Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry?

Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Fri, 19 Dec 2003 Carl Elliott is a clear eyed academic who teaches bioethics at the University of Minnesota . He is currently a visiting associate professor at School of Social Sciences . . . Continue reading →

Pediatric Cardiologist Explains: The crucial health stat you’ve never heard of_Slate

Dr. Sanghavi provides us with a statistical reality-check by which to gauge for ourselves whether or not we should–or need not–take a  octor’s advice about starting a medical treatment for a speculated risk–rather than evidence of illness. Continue reading →

Big Pharma: The Fool’s Gold that Heals_New Book

Big Pharma by Jacky Law reveals that in essence, most of the pharmaceutical industry’s claims are false; it is not the drug, but the placebo effect whose potency deserves almost all of the credit for any health improvement:
Continue reading →

Ethics, Conflict of Interest, first ever public response by David Healy, MD, to James Coyne, PhD, attack in AJOB

The Columbia lecture was originally scheduled as a debate between David Healy, MD and James Coyne, PhD. The debate did not take place, and Dr. Coyne subsequently lectured in Rutgers the following week. The lecture covered the main points Dr. Coyne makes . . . Continue reading →

Conflict of Interest

Conflict of Interest: Profits vs Safety Congressional Investigations US Senators Pharmaceutical industry holdings, 2004: http://www.consumerwatchdog.org/resources/SenPharma.pdf Oct 12: How Did the Vioxx Debacle Happen? USA Today / Lancet Oct 4: Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry Oct 3: BBC PANORAMA . . . Continue reading →

How the Drug Industry Is Branding Itself With Bioethics

Dr. Carl Elliott's insightful essay in SLATE:: Why do drug companies want to give money to bioethicists in the first place? In the public relations business, this approach is called "third-party strategy." Continue reading →

Conflicts of Interest in Clinical Trials

Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine

The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval. Continue reading →

Sharav Presentation before US Army Medical Dept., May 6, 2002

CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S. ARMY MEDICAL DEPARTMENT And THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCMENT OF MILITARY MEDICINE May 5-7, 2002 The cornerstone of public trust in medical . . . Continue reading →